Amicus Therapeutics, Inc.
FOLDDelisted Apr 27, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001178879
Amicus Therapeutics, Inc. was delisted on Apr 27, 2026; its insiders filed their last Form 4 on Apr 27, 2026; 298 institutions reported holding it in 13F filings for Q1 2026, worth $4.81B in total; Soros Fund Management was the only superinvestor holding it.
Q2 2021 vs. Q1 2021
How the institutions holding Amicus Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Of which not filed for Q2 2021 | Q2 2021 | Change |
|---|---|---|---|---|
| Holders | 259 | 2 | 235 | −22 |
| Shares | 276.4M | 30.4K | 276.9M | +566.4K (+0.2%) |
| Value | $2.74B | $300.0K | $2.67B | −$68.8M (−2.5%) |
2 institutions that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (32)
Institutions that held Amicus Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (54)
Institutions that held Amicus Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
Not filed for Q2 2021 yet (2)
Institutions that held Amicus Therapeutics, Inc. at the end of Q1 2021 and haven't filed a 13F for Q2 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Amundi Asset Management US, Inc. | 17,500 | $173.0K |
| E Fund Management Co., Ltd. | 12,862 | $127.0K |